Exits continue at FDA, as more staff in drug office follow fired colleagues out the door
The FDA office that approves new drugs is seeing more staff leave in early retirements, following broad cuts this month that targeted almost 20% of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
